Status:
COMPLETED
Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Lead Sponsor:
Johns Hopkins University
Conditions:
Atopic Keratoconjunctivitis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Atopic keratoconjunctivitis (AKC) is a rare type of ocular allergy that is often associated with eczema. Over time, the complications from this disease process lead to loss of vision due to continual ...
Detailed Description
Atopic keratoconjunctivitis (AKC) is a rare type of ocular allergy that is often associated with eczema. Over time, the complications from this disease process lead to loss of vision due to continual ...
Eligibility Criteria
Inclusion
- Patient has known diagnosis of atopic keratoconjunctivitis
- Patient has been on cyclosporine 0.05% eye drops for control of atopic keratoconjunctivitis
- Patient has been followed up for at least for 1 year
- Patient is able to give informed consent
- Patient is able to tolerate a full ophthalmic exam
Exclusion
- Patient has any other diagnosis (i.c. vernal keratoconjunctivitis, giant papillary conjunctivitis) that may alter the clinical appearance or behavior of their ocular surface)
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00987467
Start Date
August 1 2007
End Date
September 1 2009
Last Update
April 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Hospital - Wilmer Eye Institute
Baltimore, Maryland, United States, 21287